Literature DB >> 31605161

[Revised S3 guidelines on schizophrenia : Developmental process and selected recommendations].

Alkomiet Hasan1, Peter Falkai2, Isabel Lehmann3, Birgit Janssen4, Thomas Wobrock5,6, Jürgen Zielasek3, Wolfgang Gaebel7.   

Abstract

Schizophrenia is one of the most severe mental diseases and leads to significant personal and social impairments for affected persons. The illness is characterized by frequent relapses, results in increased mortality and is associated with the highest socioeconomic costs of all diseases. Moreover, patients with schizophrenia are often stigmatized in everyday life and also in most treatment settings. In 1998 the first German schizophrenia guidelines were published, followed by the first S3 guidelines for schizophrenia in 2006. The revision process started in 2012 coordinated by the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) and the revised guidelines were published in 2019. The target group for the revised S3 guidelines includes all persons involved in the care of patients with schizophrenia in all sectors of the German healthcare system, including decision makers and insurance funds. Starting with an introduction of the biological, clinical and epidemiological basis of the disorder, recommendations for the diagnostics of schizophrenia, the detection of comorbidities, the use of antipsychotic medication and other somatic procedures, for psychotherapy, psychosocial interventions, handling of special treatment conditions and rehabilitation are made. Finally, recommendations for an evidence-based and optimal coordination within the healthcare system are made, followed by a discussion of the cost-effectiveness of treatment and presentation of strategies for improved quality management. The most important aspect of the revised S3 guidelines on schizophrenia is the multiprofessional cooperation in all phases of the disorder and an empathic and respectful therapeutic alliance.

Entities:  

Keywords:  Care coordination; Cost-effectiveness; Differential diagnostics; Rehabilitation; Treatment principles

Year:  2020        PMID: 31605161     DOI: 10.1007/s00115-019-00813-y

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  5 in total

1.  [Assessment of quality indicators with routine data: Presentation of a feasibility test in ten specialist clinics for psychiatry and psychotherapy].

Authors:  I Großimlinghaus; P Falkai; W Gaebel; A Hasan; M Jänner; B Janssen; D Reich-Erkelenz; L Grüber; V Böttcher; T Wobrock; J Zielasek
Journal:  Nervenarzt       Date:  2015-11       Impact factor: 1.214

2.  [DGPPN recommendations on quality indicators for schizophrenia].

Authors:  I Großimlinghaus; I Hauth; P Falkai; B Janssen; A Deister; A Meyer-Lindenberg; C Roth-Sackenheim; F Schneider; T Wobrock; R Zeidler; W Gaebel
Journal:  Nervenarzt       Date:  2017-07       Impact factor: 1.214

Review 3.  [German S3 guidelines on avoidance of coercion: prevention and therapy of aggressive behavior in adults].

Authors:  Tilman Steinert; Sophie Hirsch
Journal:  Nervenarzt       Date:  2020-07       Impact factor: 1.214

4.  Recognition and management of psychosis and schizophrenia in children and young people: summary of NICE guidance.

Authors:  Tim Kendall; Chris Hollis; Megan Stafford; Clare Taylor
Journal:  BMJ       Date:  2013-01-23

Review 5.  Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

Authors:  Oliver D Howes; Rob McCutcheon; Ofer Agid; Andrea de Bartolomeis; Nico J M van Beveren; Michael L Birnbaum; Michael A P Bloomfield; Rodrigo A Bressan; Robert W Buchanan; William T Carpenter; David J Castle; Leslie Citrome; Zafiris J Daskalakis; Michael Davidson; Richard J Drake; Serdar Dursun; Bjørn H Ebdrup; Helio Elkis; Peter Falkai; W Wolfgang Fleischacker; Ary Gadelha; Fiona Gaughran; Birte Y Glenthøj; Ariel Graff-Guerrero; Jaime E C Hallak; William G Honer; James Kennedy; Bruce J Kinon; Stephen M Lawrie; Jimmy Lee; F Markus Leweke; James H MacCabe; Carolyn B McNabb; Herbert Meltzer; Hans-Jürgen Möller; Shinchiro Nakajima; Christos Pantelis; Tiago Reis Marques; Gary Remington; Susan L Rossell; Bruce R Russell; Cynthia O Siu; Takefumi Suzuki; Iris E Sommer; David Taylor; Neil Thomas; Alp Üçok; Daniel Umbricht; James T R Walters; John Kane; Christoph U Correll
Journal:  Am J Psychiatry       Date:  2016-12-06       Impact factor: 18.112

  5 in total
  2 in total

1.  Gender Differences in the Psychopharmacological Treatment of Forensic In-Patients With Schizophrenia.

Authors:  Juliane Mayer; Nenad Vasic; Viviane Wolf; Ivonne Steiner; Verena Klein; Michael Fritz; Philipp Rothe; Judith Streb; Manuela Dudeck
Journal:  Front Psychiatry       Date:  2022-07-15       Impact factor: 5.435

Review 2.  [Transcranial electrical brain stimulation methods for treatment of negative symptoms in schizophrenia].

Authors:  Nikolas Haller; Alkomiet Hasan; Frank Padberg; Wolfgang Strube; Leandro da Costa Lane Valiengo; Andre R Brunoni; Jerome Brunelin; Ulrich Palm
Journal:  Nervenarzt       Date:  2021-01-25       Impact factor: 1.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.